| Ytd | 11.01% | |
| 1y | 105.34% |
| Open | 53.94 | Prev Close | 53.76 | Low | 53.94 | High | 53.94 | Mkt Cap | 2.32B |
| Vol | 10.11K | Avg Vol | 686.60K | EPS | -1.08 | P/E | -49.78 | Forward P/E | 12.68 |
| Beta | 0.68 | Short Ratio | 8.59 | Inst. Own | 101.75% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 08-05 | 50-d Avg | 59.35 | 200-d Avg | 40.94 | 1yr Est | 87.09 |
ANAB News
AnaptysBio, Inc. (NASDAQ: ANAB - Get Free Report) rose 5.3% during mid-day trading on Friday. The co
GSK reports positive interim phase II AZUR-1 data as Jemperli meets the primary endpoint in rectal c
U.S. stock futures mixed, Nasdaq 100 up 100 points. FedEx falls after Q4 results, beating estimates
HC Wainwright & Co. analyst Joseph Pantginis assumes AnaptysBio (NASDAQ:ANAB) with a Buy rati
Here is how AnaptysBio, Inc. (ANAB) and Electromed, Inc. (ELMD) have performed compared to their sec
The consensus price target hints at a 38.8% upside potential for AnaptysBio (ANAB). While empirical
After losing some value lately, a hammer chart pattern has been formed for AnaptysBio (ANAB), indica
UBS analyst Michael Yee maintains AnaptysBio (NASDAQ:ANAB) with a Buy and raises the price target
Barclays analyst Etzer Darout maintains AnaptysBio (NASDAQ:ANAB) with a Overweight and raises the
AnaptysBio (NASDAQ:ANAB) reported quarterly losses of $(1.84) per share which missed the analyst con
SAN DIEGO, May 12, 2026 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a company focused on ma
AnaptysBio, Inc. (NASDAQ:ANAB), a company focused on managing the financial collaborations for Jempe
SAN DIEGO, May 11, 2026 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a company focused on ma
Does AnaptysBio, Inc. (ANAB) have what it takes to be a top stock pick for momentum investors? Let's
Here is how AnaptysBio, Inc. (ANAB) and Coherus Oncology (CHRS) have performed compared to their sec
SAN DIEGO, May 04, 2026 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a company focused on ma
Piper Sandler analyst Yasmeen Rahimi maintains AnaptysBio (NASDAQ:ANAB) with a Overweight and low
WASHINGTON, April 28, 2026 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today a
Arcus Biosciences (RCUS) doesn't possess the right combination of the two key ingredients for a like
AnaptysBio shares jump 12% after a favorable Delaware Court ruling in the Tesaro dispute. See the la
AnaptysBio (ANAB) doesn't possess the right combination of the two key ingredients for a likely earn
U.S. stocks were lower, Dow Jones fell 0.1% on Monday. XOMA shares rose on Ligand's plans to acq
AnaptysBio (ANAB) was a big mover last session on higher-than-average trading volume. The latest tre
GSK PLC's (LSE:GSK, NYSE:GSK) oncology subsidiary TESARO has secured a partial legal victory after a
Ruling preserves current contracted royalty rates and rejects Tesaro's request for any royalty r
Ruling preserves current contracted royalty rates and rejects Tesaro's request for any royalty reduc
SAN DIEGO, April 20, 2026 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a royalty management
AnaptysBio, Inc. (NASDAQ: ANAB - Get Free Report) Director John Schmid sold 20,645 shares of the fir
AnaptysBio, Inc. (Nasdaq: ANAB) today announced that its Board of Directors has authorized a Stock R
SAN DIEGO, March 27, 2026 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB) today announced that i
On Wednesday, 216 stocks hit new 52-week lows.